Company intelligence / Profile preview
Neukidney
Texas, United Statesneukidney.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Neukidney has developed a proprietary conduit system designed to deliver cellular therapies directly into the kidneys. Preclinical studies have demonstrated safety in animal models. The technology aims to regenerate dying kidney tissue, potentially reducing the need for dialysis or transplantation. No human clinical results are available yet; regulatory approval has not been obtained.
- Therapeutic areas
- Nephrology
- Modalities
- Cellular therapies (including stem cells and non-stem cells)Platelet-based therapiesSmall molecule drug
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Neukidney.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neukidney.